Revenue has successfully transitioned from zero in 2024 to $3.5M in 2026Q1, yet this growth is currently overshadowed by SG&A expenses of $10.3M that result in a net margin of -183.3%.
| Sales/Revenue | 10.83M | - | - | - | - | - | - |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | - | - | - | - | - | - |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 9.35M | 8.3M | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | 86.36% | 81.26% | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - |
| Operating Expenses | 36.42M | 30.97M | 11.86M | 9.62M | 13.47M | 11.57M | 5.71M |
| OpEx % of Revenue | - | 302.98% | - | - | - | - | - |
| Selling, General & Admin | 33.6M | 29.08M | 7.32M | 4.69M | 4.05M | 3.38M | 950.44K |
| SG&A % of Revenue | - | 284.49% | - | - | - | - | - |
| Research & Development | 0 | - | - | - | - | - | - |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | - | - | - | - | - | - |
| Operating Income | -27.07M | -22.66M | -11.86M | -9.62M | -13.47M | -11.57M | -5.71M |
| Operating Margin % | -250.06% | -221.72% | - | - | - | - | - |
| Operating Income Growth % | - | -91.06% | -23.32% | 28.58% | -16.4% | -102.78% | - |
| EBITDA | -26.99M | -22.6M | -11.78M | -9.53M | -13.37M | -11.48M | -5.62M |
| EBITDA Margin % | -249.32% | -221.15% | - | - | - | - | - |
| EBITDA Growth % | -162.08% | -91.88% | -23.56% | 28.72% | -16.52% | -104.11% | - |
| D&A (Non-Cash Add-back) | 81.06K | 58.57K | 81.22K | 84.48K | 90.92K | 89.88K | 81.44K |
| EBIT | -27.07M | -22.66M | -14.45M | -13.7M | -11.94M | -19.02M | -5.01M |
| Net Interest Income | 1.94M | 1.9M | -24.11K | -60.91K | -170.96K | -526.09K | -747.78K |
| Interest Income | 1.94M | 1.9M | 161.66K | 6.8K | 1.93K | 2.07K | 22.59K |
| Interest Expense | 0 | 0 | 185.78K | 67.71K | 172.88K | 528.16K | 770.37K |
| Other Income/Expense | 0 | - | - | - | - | - | - |
| Pretax Income | -25.14M | -20.67M | -14.64M | -13.77M | -12.11M | -19.55M | -5.78M |
| Pretax Margin % | -232.24% | -202.24% | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -25.14M | -20.67M | -14.64M | -13.77M | -12.11M | -19.55M | -5.78M |
| Net Margin % | -232.24% | -202.24% | - | - | - | - | - |
| Net Income Growth % | -115.98% | -41.22% | -6.28% | -13.68% | 38.02% | -237.9% | - |
| Net Income (Continuing) | -25.14M | -20.67M | -14.64M | -13.77M | -12.11M | -19.55M | -5.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.15 | -1.17 | -2.02 | -3.84 | -4.50 | -9.25 | -2.79 |
| EPS Growth % | -13.47% | 42.08% | 47.4% | 14.67% | 51.35% | -231.54% | - |
| EPS (Basic) | - | -1.17 | -2.02 | -3.84 | -4.50 | -9.25 | -2.79 |
| Diluted Shares Outstanding | 21.93M | 17.68M | 7.25M | 3.59M | 2.72M | 2.13M | 2.07M |
| Basic Shares Outstanding | 21.76M | 17.68M | 7.25M | 3.59M | 2.72M | 2.13M | 2.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Commercial execution and liquidity
According to recent financial disclosures, Alpha Cognition has successfully transitioned from zero revenue in 2024 to $3.5M in 2026Q1, signaling an early-stage shift toward commercialization that warrants close monitoring to determine if this growth represents sustainable product adoption or merely non-recurring milestone-based licensing inflows.
The emergence of top-line revenue suggests the company is moving past its purely clinical-stage roots, yet the lack of historical consistency makes it difficult to project future growth durability. Investors should interpret this revenue as a nascent indicator of market interest rather than a proven trajectory of recurring prescription volume.
As reported in quarterly filings, Alpha Cognition's SG&A expenses reached $10.3M in 2026Q1, significantly exceeding the $3.5M in revenue, which highlights the substantial capital intensity required to support the company's current commercial infrastructure and ongoing research initiatives during this critical launch phase.
The cost structure is heavily skewed toward fixed overhead, which creates a high operating leverage hurdle that the company has yet to overcome. This expense profile suggests that management is prioritizing market entry and infrastructure build-out over immediate profitability, leaving the firm vulnerable to cash depletion if revenue does not scale rapidly.
Based on the provided income statement data, the company's operating margin of -221.72% reflects a structural inability to cover fixed costs, as operating losses continue to widen despite the recent appearance of revenue, indicating that the business model remains in a high-burn, pre-profitability phase.
The disconnect between gross profit and operating income suggests that the company is currently unable to achieve economies of scale. Without a significant inflection in prescription volume, the current operating leverage appears insufficient to support the existing cost base, necessitating careful observation of future quarterly expense management.
Analysis of the income statement reveals that stock-based compensation reached $1.4M in 2026Q1, representing a meaningful portion of the company's operating expenses and suggesting that reported net losses may be partially mitigated by non-cash accounting treatments that do not reflect the underlying cash burn.
The reliance on equity-based incentives to manage cash outflows may mask the true economic cost of operations for shareholders. Investors should adjust for these non-cash items to better understand the actual cash runway and the potential for future dilution as the company continues to fund its commercial expansion.
Quick answers to the most common questions about buying ACOG stock.
Alpha Cognition Inc. Common Stock (ACOG) reported a net loss of $20.7M for the fiscal year ending 2025.
Alpha Cognition Inc. Common Stock (ACOG) reported an operating income of $-22.7M, resulting in an operating profit margin of -221.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Alpha Cognition Inc. Common Stock (ACOG) generated $8.3M in gross profit for the year, representing a gross profit margin of 81.3%. This demonstrates the company's core pricing power and production efficiency.